Shares lose 85% of their value after failure on key lupus drug
Thursday 19 Apr 2018 Author: Lisa-Marie Janes

Shares in drug discovery company ImmuPharma (IMM:AIM) collapsed on 17 April showing how risky early stage drug development really is.

The company’s lead drug Lupuzor failed to show meaningful statistical benefits over a placebo in Phase III trials. Lupus is an autoimmune disease that affects millions, famously including American singer and actress Selena Gomez.

ImmuPharma’s share price crashed 85% to 22.7p on the news, leaving the firm’s market value at just £32m. (LMJ)

‹ Previous2018-04-19Next ›